Cargando…
Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial
BACKGROUND: Deficiencies in membrane polyunsaturated fatty acids (PUFA) such as omega-3 (n-3) fatty acids are thought to contribute to the pathophysiological processes underlying psychotic disorders. Emerging evidence suggests that the levels of PUFA are related to clinical symptoms but significant...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562242/ https://www.ncbi.nlm.nih.gov/pubmed/31244693 http://dx.doi.org/10.3389/fpsyt.2019.00393 |
_version_ | 1783426257768153088 |
---|---|
author | Berger, Maximus Nelson, Barnaby Markulev, Connie Yuen, Hok Pan Schäfer, Miriam R. Mossaheb, Nilufar Schlögelhofer, Monika Smesny, Stefan Hickie, Ian B. Berger, Gregor E. Chen, Eric Y. H. de Haan, Lieuwe Nieman, Dorien H. Nordentoft, Merete Riecher-Rössler, Anita Verma, Swapna Mitchell, Todd W. Meyer, Barbara J. Thompson, Andrew Yung, Alison Ruth McGorry, Patrick D. Amminger, G. Paul |
author_facet | Berger, Maximus Nelson, Barnaby Markulev, Connie Yuen, Hok Pan Schäfer, Miriam R. Mossaheb, Nilufar Schlögelhofer, Monika Smesny, Stefan Hickie, Ian B. Berger, Gregor E. Chen, Eric Y. H. de Haan, Lieuwe Nieman, Dorien H. Nordentoft, Merete Riecher-Rössler, Anita Verma, Swapna Mitchell, Todd W. Meyer, Barbara J. Thompson, Andrew Yung, Alison Ruth McGorry, Patrick D. Amminger, G. Paul |
author_sort | Berger, Maximus |
collection | PubMed |
description | BACKGROUND: Deficiencies in membrane polyunsaturated fatty acids (PUFA) such as omega-3 (n-3) fatty acids are thought to contribute to the pathophysiological processes underlying psychotic disorders. Emerging evidence suggests that the levels of PUFA are related to clinical symptoms but significant heterogeneity exists between studies. Here, we investigated associations of membrane PUFA with clinical symptoms and functioning in a large sample of individuals at ultra-high risk (UHR) for psychosis. METHODS: A total of 285 participants of the NEURAPRO clinical trial were investigated for erythrocyte PUFA levels, including the n-3 index, n-6/n-3 PUFA ratio, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA). Severity of general psychopathology [Brief Psychiatric Rating Scale (BPRS)], psychotic symptoms (BPRS psychosis subscale), negative symptoms [Scale for the Assessment of Negative Symptoms (SANS)], manic symptoms [Young Mania Rating Scale (YMRS)], depressive symptoms [Montgomery Asberg Depression Rating Scale (MADRS)], and functioning [Social and Occupational Functioning Scale (SOFAS), Global Functioning Social (GF-S) and Role (GF-R) scales] were assessed concurrently. Partial correlation taking into account the effects of gender, age, and smoking was used to examine the relationship between PUFAs and symptoms severity. RESULTS: The n-3 index negatively correlated with the severity of general psychopathology, psychotic symptoms, depressive symptoms, and manic symptoms. The n-6/n-3 PUFA ratio positively correlated with severity of psychotic and depressive symptoms. The n-3 PUFA DHA negatively correlated with the severity of general psychopathology, positive, manic, and depressive symptoms. EPA negatively correlated with manic symptoms. Nervonic acid, an n-9 monounsaturated fatty acid, positively correlated with general psychopathology, positive and negative symptoms, depressive symptoms, and manic symptoms. The long-chain saturated fatty acid tetracosanoic acid positively correlated with general psychopathology, positive, manic, and depressive symptoms. CONCLUSIONS: Partially consistent with a previous study, psychotic symptoms, depressive symptoms, and symptoms of mania were associated with several classes of FAs in the present study. These findings support the relevance of membrane fatty acids for the onset of psychotic symptoms and indicate that FAs should be further evaluated as biomarkers in the UHR for psychosis group. CLINICAL TRIAL REGISTRATION: ANZCTR, identifier: 12608000475347 |
format | Online Article Text |
id | pubmed-6562242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65622422019-06-26 Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial Berger, Maximus Nelson, Barnaby Markulev, Connie Yuen, Hok Pan Schäfer, Miriam R. Mossaheb, Nilufar Schlögelhofer, Monika Smesny, Stefan Hickie, Ian B. Berger, Gregor E. Chen, Eric Y. H. de Haan, Lieuwe Nieman, Dorien H. Nordentoft, Merete Riecher-Rössler, Anita Verma, Swapna Mitchell, Todd W. Meyer, Barbara J. Thompson, Andrew Yung, Alison Ruth McGorry, Patrick D. Amminger, G. Paul Front Psychiatry Psychiatry BACKGROUND: Deficiencies in membrane polyunsaturated fatty acids (PUFA) such as omega-3 (n-3) fatty acids are thought to contribute to the pathophysiological processes underlying psychotic disorders. Emerging evidence suggests that the levels of PUFA are related to clinical symptoms but significant heterogeneity exists between studies. Here, we investigated associations of membrane PUFA with clinical symptoms and functioning in a large sample of individuals at ultra-high risk (UHR) for psychosis. METHODS: A total of 285 participants of the NEURAPRO clinical trial were investigated for erythrocyte PUFA levels, including the n-3 index, n-6/n-3 PUFA ratio, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA). Severity of general psychopathology [Brief Psychiatric Rating Scale (BPRS)], psychotic symptoms (BPRS psychosis subscale), negative symptoms [Scale for the Assessment of Negative Symptoms (SANS)], manic symptoms [Young Mania Rating Scale (YMRS)], depressive symptoms [Montgomery Asberg Depression Rating Scale (MADRS)], and functioning [Social and Occupational Functioning Scale (SOFAS), Global Functioning Social (GF-S) and Role (GF-R) scales] were assessed concurrently. Partial correlation taking into account the effects of gender, age, and smoking was used to examine the relationship between PUFAs and symptoms severity. RESULTS: The n-3 index negatively correlated with the severity of general psychopathology, psychotic symptoms, depressive symptoms, and manic symptoms. The n-6/n-3 PUFA ratio positively correlated with severity of psychotic and depressive symptoms. The n-3 PUFA DHA negatively correlated with the severity of general psychopathology, positive, manic, and depressive symptoms. EPA negatively correlated with manic symptoms. Nervonic acid, an n-9 monounsaturated fatty acid, positively correlated with general psychopathology, positive and negative symptoms, depressive symptoms, and manic symptoms. The long-chain saturated fatty acid tetracosanoic acid positively correlated with general psychopathology, positive, manic, and depressive symptoms. CONCLUSIONS: Partially consistent with a previous study, psychotic symptoms, depressive symptoms, and symptoms of mania were associated with several classes of FAs in the present study. These findings support the relevance of membrane fatty acids for the onset of psychotic symptoms and indicate that FAs should be further evaluated as biomarkers in the UHR for psychosis group. CLINICAL TRIAL REGISTRATION: ANZCTR, identifier: 12608000475347 Frontiers Media S.A. 2019-06-06 /pmc/articles/PMC6562242/ /pubmed/31244693 http://dx.doi.org/10.3389/fpsyt.2019.00393 Text en Copyright © 2019 Berger, Nelson, Markulev, Yuen, Schäfer, Mossaheb, Schlögelhofer, Smesny, Hickie, Berger, Chen, de Haan, Nieman, Nordentoft, Riecher-Rössler, Verma, Mitchell, Meyer, Thompson, Yung, McGorry and Amminger http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Berger, Maximus Nelson, Barnaby Markulev, Connie Yuen, Hok Pan Schäfer, Miriam R. Mossaheb, Nilufar Schlögelhofer, Monika Smesny, Stefan Hickie, Ian B. Berger, Gregor E. Chen, Eric Y. H. de Haan, Lieuwe Nieman, Dorien H. Nordentoft, Merete Riecher-Rössler, Anita Verma, Swapna Mitchell, Todd W. Meyer, Barbara J. Thompson, Andrew Yung, Alison Ruth McGorry, Patrick D. Amminger, G. Paul Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial |
title | Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial |
title_full | Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial |
title_fullStr | Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial |
title_full_unstemmed | Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial |
title_short | Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial |
title_sort | relationship between polyunsaturated fatty acids and psychopathology in the neurapro clinical trial |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562242/ https://www.ncbi.nlm.nih.gov/pubmed/31244693 http://dx.doi.org/10.3389/fpsyt.2019.00393 |
work_keys_str_mv | AT bergermaximus relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT nelsonbarnaby relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT markulevconnie relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT yuenhokpan relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT schafermiriamr relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT mossahebnilufar relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT schlogelhofermonika relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT smesnystefan relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT hickieianb relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT bergergregore relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT chenericyh relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT dehaanlieuwe relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT niemandorienh relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT nordentoftmerete relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT riecherrossleranita relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT vermaswapna relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT mitchelltoddw relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT meyerbarbaraj relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT thompsonandrew relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT yungalisonruth relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT mcgorrypatrickd relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial AT ammingergpaul relationshipbetweenpolyunsaturatedfattyacidsandpsychopathologyintheneuraproclinicaltrial |